

PRESSURE BIOSCIENCES INC.

14 Norfolk Avenue
South Easton, MA 02375
(T) 508-230-1828
(F) 508-230-1829
info@pressurebiosciences.com

Mr. Richard T. Schumacher, CEO, President
Dr. Edmund Y. Ting, SVP of Engineering
Dr. Alexander V. Lazarev, Chief Science Officer
Dr. Nate Lawrence, Senior Advisor
Mr. Richard Thomley, Financial Advisor (ex-CFO)

STOCK OVERVIEW

Symbol:	PBIO	Recent Close:	\$2.30 (as of 08/10/19)
Exchange:	OTCQB	52-Week Range:	\$1.52 - \$4.10
Shares OS ¹ :	1.9M (8.6M FD)	Market Capitalization ² :	\$4.4M (\$20M FD)
Float:	~1.4M	Fiscal Year End:	December 31
Revenue (FY2018):	\$2.46M	Transfer Agent:	Computershare

COMPANY OVERVIEW

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development & sale of innovative, enabling, pressure-based platform solutions for the worldwide life sciences industry. Our products/services are based on three patented, pressure-enhanced platforms: (i) Pressure Cycling Technology (“PCT”), (ii) BaroFold Technology (“BaroFold”), and (iii) Ultra Shear Technology (“UST”).

The PCT Platform uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., critical steps performed by hundreds of thousands of scientists worldwide, such as cell lysis and biomolecule extraction). Our primary focus is in making our recently released, GMP-compliant, next generation PCT-based Barocycler EXTREME instrument available globally to biopharmaceutical drug manufacturers for use in the design, development, characterization and quality control of biotherapeutic drugs. The PCT Platform is also used in such areas as biomarker and target discovery, soil & plant biology, anti-bioterror, and forensics. We currently have over 300 PCT instrument systems placed in approximately 200 academic, government, pharmaceutical, and biotech research laboratories worldwide. There are over 120 independent publications highlighting the advantages of using the PCT Platform in scientific research studies, many from worldwide key opinion leaders. The PCT Platform is offered through the Company’s Research Products & Services Group.

The BaroFold Platform can be used to significantly impact and improve the quality of protein therapeutics. It employs high pressure for the disaggregation and controlled refolding of proteins to their native structures at yields and efficiencies not achievable using existing technologies. The BaroFold Platform has been shown to remove protein aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy and safety for both new-drug entities and biosimilar products. The BaroFold Platform can help companies create novel protein therapeutics, accelerate therapeutic protein development, manufacture follow-on biologics, and enable life-cycle management of protein therapeutics. It is scalable and practical for standard manufacturing processes. This unique technology platform can help protein-based biopharmaceutical companies create and manufacture high quality, novel protein therapeutics and lower the cost of existing formulations. Research and manufacturing licenses are available.

The UST Platform is based on the use of intense shear forces from ultra-high pressure (greater than 20,000 psi) valve discharge. UST has been shown to turn hydrophobic extracts into stable, water-soluble formulations on a small, laboratory scale. The UST Platform offers the potential to produce stable nanoemulsions of oil-like products in water. Such formulations could potentially have enormous success in many markets, including inks, paints, and cosmetics, as well as in pharmaceuticals and nutraceuticals, such as medically important plant oil extracts, i.e., making CBD-enriched plant oil water soluble. We believe that UST has the potential to play a significant role in a number of commercially important areas, including (i) the creation of stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water), and (ii) the preparation of higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies, e.g., dairy products. The UST Platform is currently being developed for commercialization.

1. Shares Outstanding (as of March 31, 2019) – includes approximately 1.9M common shares and 6.7M common share equivalents from Preferred Stock Series D, G, H, J, K, and AA on an as-converted basis.
2. Fully Diluted Market Capitalization is calculated using Common Stock OS and Common Equivalent Shares OS on a Fully Diluted basis.

INVESTMENT HIGHLIGHTS

- Seasoned Management Team & Board of Directors
 - Three Novel, Enabling, Patent Protected & Proprietary Pressure-based Platforms
 - Proven Core Technology with Multiple Applications (Over 300 PCT Systems Installed Globally)
 - Sales into the Research Market (fast market penetration with minimal approvals required)
 - Increasing Number of 3rd Party Publications from Marquee Laboratories
 - PCT Breaks Through Bottlenecks to Enable and Accelerate Scientific Discovery & QC in Drug Development
 - BaroFold Technology Impacts/Improves Protein Drug Therapeutics through Disaggregation and Refolding
 - UST Produces Highly Stable Nanoemulsions for Many Applications, Including CBD, Cosmetics, and Food
 - Significant Worldwide Market Opportunities: PCT (BioPharma \$526B); BaroFold (Drug Processing \$44B); UST (CBD \$89B; Cosmetics \$805B; BioPharma Drug Delivery \$900B; Food and Beverages \$5.65T)
-

RECENT & KEY ANNOUNCEMENTS (2019/2018)

- **July 25, 2019:** the Company announced the first close and customer for its revolutionary water-soluble CBD manufacturing system, the BaroShear K45.
 - July 24: the Company announced it had received the second major contract utilizing its BaroFold Protein Refolding and Disaggregation Biopharma Services Business and that it expected a significant increase in its services revenue in 2019 and beyond.
 - June 27: the Company enters the CBD market with the launch of a novel instrument system to revolutionize manufacturing of high quality, water-soluble CBD Oil.
 - June 26: the Company achieved the first major milestone in the development of a potential breakthrough processing method for higher quality and safer food and beverages – with a focus on dairy products.
 - June 19: the Company announced that its ultra-high pressure HUB instrument platform was shown to be highly effective in studies to develop improved methods for food safety, addressing the need for new ways to prevent serious food-borne diseases caused by bacteria such as *E. coli* and *Listeria*.
 - June 12: the Company announced that its patented PCT Platform was prominently featured in a record 15 presentations at a major international science conference, with a common focus on the platform's significant use in cancer research, protein function, molecular biology, and biomarker discovery.
 - May 16, 2019: the Company reported first quarter 2019 financial results. Among the areas highlighted were the results for the newly created Biopharma and UST Contract Services area, where Q1 2019 revenue significantly exceeded Contract Services revenue for all four quarters of 2018 combined.
 - May 1: the Company announced that on September 9, 2019 Richard T. Schumacher would step down as CEO. Dr. Brad Young, PBI's Chief Commercial Officer, was announced as the Board's new CEO designee.
 - April 25: the Company released its Q4 and FY 2018 financial results. Highlights: (a) Q4 2018 total revenue increased 37% over Q4 2017, setting a new record quarterly high; (b) FY 2018 total revenue increased 10% over FY 2017, setting a new record annual high; (c) initial revenue reported from new BiPharma Services and UST businesses; and (d) balance sheet improved with significant (\$13.6M) conversion of debt to equity.
 - April 2: the Company released a new short video demonstrating the ability of the Company's proprietary UST platform to create water-soluble CBD oil that disperses instantly when infused into soft drinks, sports drinks, and beer for enhanced quality and absorption.
 - March 4: the Company announced a collaboration with the world renown Steinbeis Centre (Germany) to develop a revolutionary method based on optimizing disease-fighting antibodies. The method will combine PBI's patented PCT platform with the Centre's innovative PROTEX-MS platform.
 - February 21: the Company released scientific analyses confirming important benefits from processing CBD Oil with PBI's UST platform: analyses showed UST-prepared CBD Oil solutions met challenging nanoemulsion specifications and exhibited minimal loss during processing.
 - February 13: the Company announced the release of a short video demonstrating the use of its prototype UST platform to make water-soluble CBD Oil, offering a solution to CBD Absorption Issues in food and beverages.
 - January 29: the Company announced a collaboration with nutraceuticals manufacturer NutraFuels, Inc. for the development of high quality, water-soluble nanoemulsion-based nutraceuticals.
 - **January 7, 2019:** the Company announced commercial launch of its unique biopharmaceuticals contract services business, offering improved manufacturing for protein therapeutic candidates (a \$250B global market).
 - December 18: Major International Research Center Reported that the Company's PCT Platform Could Play a Significant Role in Improving Cancer Diagnosis and Treatment.
 - November 15: the Company announced the development of a proprietary method for water soluble oils, which it believed could open up major new opportunities in multiple markets, e.g., the CBD Oil and cosmetics markets.
 - November 9: the Company announced achievement of the first major milestone in the development of its Ultra Shear Technology ("UST") Program: development of the first working prototype of the UST Platform System.
 - **July 19, 2018:** the Company announced it was developing a potential breakthrough processing method - based on their patented Ultra Shear Technology - for high quality, shelf-stable milk and other dairy products.
-

BOARD OF DIRECTORS

- Mr. Jeffrey N. Peterson, Chairman
- Mr. Kevin A. Pollack, Esq.
- Mr. Vito Mangiardi
- Dr. Mickey Urdea
- Mr. Richard T. Schumacher

8/10/2019